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Abstract: Glycosylation is an important post-translational modification for both intracellular and
secreted proteins. For glycosylation to occur, cargo must be transported after synthesis through
the different compartments of the Golgi apparatus where distinct monosaccharides are sequentially
bound and trimmed, resulting in increasingly complex branched glycan structures. Of utmost
importance for this process is the intraorganellar environment of the Golgi. Each Golgi compartment
has a distinct pH, which is maintained by the vacuolar H+-ATPase (V-ATPase). Moreover, tethering
factors such as Golgins and the conserved oligomeric Golgi (COG) complex, in concert with coatomer
(COPI) and soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-mediated
membrane fusion, efficiently deliver glycosylation enzymes to the right Golgi compartment. Together,
these factors maintain intra-Golgi trafficking of proteins involved in glycosylation and thereby
enable proper glycosylation. However, pathogenic mutations in these factors can cause defective
glycosylation and lead to diseases with a wide variety of symptoms such as liver dysfunction and
skin and bone disorders. Collectively, this group of disorders is known as congenital disorders of
glycosylation (CDG). Recent technological advances have enabled the robust identification of novel
CDGs related to membrane trafficking components. In this review, we highlight differences and
similarities between membrane trafficking-related CDGs.
Keywords: post-translational modification; glycosylation; membrane trafficking; Golgi apparatus;
secretory pathway; congenital disorders of glycosylation
1. Introduction
The conjugation of oligosaccharide structures to proteins, glycosylation, is a ubiquitous and
fundamental post-translational modification found in all domains of life. Glycosylation is not
only important for the structure and function of proteins, but also for their transit and selective
targeting through the secretory pathway [1–7]. In mammals, approximately 700 proteins are necessary
for generating the full diversity of over 7000 glycan structures [8–12]. The addition of glycan
structures in vertebrates is a sequential process and involves both the addition of monosaccharides
via glycosyltransferases and the trimming of glycans by glycosidases [13]. Only ten different
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monosaccharides are required to build the full glycan spectrum: fucose (Fuc), galactose (Gal),
glucose (Glc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), glucuronic acid
(GlcA), mannose (Man), sialic acid (SA, also known as neuraminic acid), xylose (Xyl), and recently
identified ribitol [8,10,11,14].
In vertebrates, N-glycan synthesis is initiated in the ER as a 14 monosaccharide precursor on
the carrier lipid dolichol. During translation, this glycan is transferred by oligosaccharyltransferase
(OST) [15–17] from dolichol to the nascent polypeptide at acceptor peptide sequons, generally
consisting of an Asn-X-(Ser/Thr) motif [18–21]. Distal glucose moieties of these immature, high
glucose and mannose containing, glycan structures are subsequently trimmed before Golgi entry;
an important step in the control of misfolded glycoproteins in the ER [5,22,23]. Glycoproteins then
exit the ER via, for instance, cargo receptor ERGIC-53 [24–26] and are transported to the Golgi
apparatus for further processing. In the Golgi, glycoproteins are trimmed, extended, and branched
until they reach their final glycan form. The mammalian Golgi apparatus is a single large perinuclear
organelle, organized into discrete compartments or cisternae [27–29]. The Golgi can be subdivided
into cis-Golgi, closest to the ER, medial-Golgi, trans-Golgi, and the trans-Golgi network (TGN),
furthest away from the nucleus. Furthermore, mammals have a pre-Golgi compartment known as
the ER-Golgi intermediate compartment (ERGIC, previously known as the vesicular-tubular cluster
(VTC)) [30,31]. Newly synthesized glycoproteins emanating from the ER enter the Golgi apparatus
at the cis-Golgi, sequentially pass through medial- and trans-Golgi, and finally, exit the Golgi at
the TGN. The compartmentalization of the Golgi allows for distinct environments containing subsets
of glycosylation enzymes [32–35], enabling sequential modifications for the formation of completely
mature glycoproteins. The organization of Golgi-resident enzymes and the Golgi apparatus itself differs
between cell types, contributing to glycoprotein diversity [28,36–39]. Two examples are the distribution
of α-mannosidases I and II, which primarily localize to the trans-Golgi in intestinal goblet cells, but are
distributed over all Golgi cisternae in hepatocytes, the functional consequences of which are currently
unknown [39].
Efficient glycosylation fully relies on the correct localization of glycosylation enzymes, as well as on
the delivery of other glycosylation machinery, such as nucleotide sugar transporters, and cargo proteins
to be glycosylated to the correct Golgi compartment. An important factor involved in the correct
trafficking of glycosylation enzymes is the maintenance of pH within the Golgi apparatus. In eukaryotic
cells, the principal proton pump for the regulation of intraorganellar pH is the vacuolar H+-ATPase
(V-ATPase). The membrane V0 domain anchors this complex in the membrane, and the V1 domain
is cytosolic [40]. The V0 domain contains six different subunits (a, d, e, c, c’, and c”). This domain
functions as a proton translocator across the membrane, which not only results in a pH gradient, but
also in a change in membrane potential, which is neutralized by counter ions such as K+ and Cl−.
The cytosolic V1 domain contains eight subunits (A-H), and its main function is ATP hydrolysis [40] to
provide the energy needed for the pH gradient. In mammals, the specificity of V-ATPase localization is
encoded in the V0a subunit, as four unique isoforms exist (V0a1-4). This is in contrast to Saccharomyces
cerevisiae, which has only two unique isoforms (Vph1p and Stv1p) [40–44]. The diversity in V0a
subunits is likely important for specific cell type-dependent functions and differential regulation of
the pH in different organelles. Isoform V0a1 is targeted to secretory vesicles and V0a2 to the Golgi
and endosomes, and V0a3, highly expressed in macrophages and osteoclasts [45,46], is enriched in
late endosomes and lysosomes, while V0a4 is mainly expressed in the kidney, inner ear, and ocular
ciliary body [47–50]. The V-ATPase ensures a constant pH in the various Golgi compartments, which
ranges from 6.7 for the cis-Golgi to 6.0 for the trans-Golgi [51]. Given the pH optima of glycosylation
enzymes, this pH gradient could restrict the activity of glycosylation enzymes to their target Golgi
compartment [52]. However, this might not be the complete explanation considering the broad
distribution of pH optima and the small differences in absolute pH between the cisternae. Instead,
or additionally, the pH-sensitive binding and release to cargo adapters might ensure correct enzyme
localization to the target Golgi compartment [53–55].
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Several models for the trafficking routes in the Golgi exist, but the most favorable model of
membrane traffic within the Golgi is the cisternal maturation model (Figure 1) [56]. Cisternal maturation
is the gradual conversion of a Golgi compartment by the delivery of proteins and lipids from more
mature Golgi compartments concomitant with the removal of Golgi proteins and lipids from previous
Golgi compartments by coatomer (coat protein complex I; COPI)-mediated retrograde membrane
trafficking [27,56]. Before membrane fusion of these COPI vesicles, a set of molecular instruments
orchestrates correct vesicle targeting to and within the Golgi. An important group of such trafficking
factors is the Golgin family, which consist of large coiled-coil proteins that associate with the Golgi
membrane. Golgins form a tentacular web in the cytosol that efficiently and selectively tethers
cargo vesicles [57–59]. Concurrently, Golgins can act as scaffolding proteins for small Rab or Arf
GTPases [60–62]. At the Golgi, Rab6 and Rab30 can recruit effectors, such as the cytoskeletal motor
protein myosin II, for vesicle trafficking [63–67]. Completing the ensemble is the conserved oligomeric
Golgi (COG) tethering complex, a hetero-octameric protein complex bridging the Golgi membrane
and COPI vesicles [68,69]. Finally, when the Golgi membrane and the uncoated COPI vesicle are
in close enough proximity, membrane fusion occurs. Membrane fusion is performed by soluble
N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins.
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As glycosylation is such an extensive process with a multitude of different factors that operate
together for sequential remodeling of glycan moieties, only slight disturbances can have major
implications on glycosylation. As such, over 100 monogenic diseases have been identified characterized
by dysfunctional glycosylation, which form a group collectively known as congenital disorders of
glycosylation (CDG) [53,70,71]. A large subset of these includes genetic variants in the prior mentioned
trafficking proteins, but also in subunits of the vacuolar H+-ATPase and its assembly factors. Recent
technological advances in CDG diagnostics have enabled more comprehensive analysis of glycosylation
disorders. Novel mass spectrometric methods to detect changes in glycosylation [72,73] together with
next-generation sequencing to detect novel genomic mutations [74,75] are a powerful combination
for the interrogation of membrane trafficking components in CDGs. This review serves to provide
a comprehensive overview of trafficking-related CDGs and to form a detailed understanding of how
Golgi trafficking influences glycosylation.
2. Membrane Trafficking Components in CDG
Efficient membrane trafficking is of utmost importance for the entire secretory pathway. In this
review, we focus on disorders directly affecting Golgi function. Therefore, other disorders affecting for
instance ER to ERGIC transport will not be discussed.
2.1. Vacuolar H+-ATPase
For efficient delivery of glycosylation enzymes to Golgi cisternae to occur, the intraorganellar pH
must allow the association of the glycosylation enzyme with a trafficking cargo receptor at the donor
compartment and release from the receptor at the receiving compartment. Given the role of pH in
intracellular trafficking and how stringent cisternal pH is regulated in the Golgi apparatus (Figure 2) [51],
alterations in pH maintenance might be expected to lead to mislocalization of glycosylation enzymes,
which in turn cause glycosylation disorders. Indeed, genetic variants in ATP6V0A2, the gene
encoding the membrane-bound V0a2 subunit of the V-ATPase localized to endosomes and TGN [49,50],
lead to glycosylation defects [48]. Patients with pathogenic variants, loss-of-function mutations
leading to a truncated protein, in ATP6V0A2 present with wrinkly skin syndrome and autosomal
recessive cutis laxa type II, both connective tissue disorders related to the secretion of elastin to
the extracellular matrix, and neurological involvement. Moreover, experiments in patient fibroblasts
with the fungal metabolite Brefeldin A (BFA), which inhibits the formation of COPI vesicles [76],
demonstrate that retrograde intra-Golgi trafficking is impaired in pathogenic ATP6V0A2 variants,
likely causing the mislocalization of glycosyltransferases. Supporting this, neutralization of the Golgi
pH with the weak base ammonium chloride or proton pump inhibitor Bafilomycin A1 also mislocalizes
glycosyltransferases [77]. Furthermore, the misregulation of Golgi pH could influence the delivery of
glycosylated cargo via the cargo receptor ERGIC53, which binds high mannose glycans in the ER in
a pH-dependent manner and transports them to the Golgi apparatus [24–26,78]. Thus, in addition to
the deviation of the pH values away from those optimal for glycosyltransferase activity, mutations
in subunits of the V-ATPase could result in mislocalization of both glycosyltransferases and their
substrates, and this likely contributes to the CDG pathology. General pH maintenance in the Golgi is
imperative for physiological glycosylation.
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Similarly, recently, a novel CDG involving the putative V-ATPase assembly factor VMA21 (ortholog
of yeast Vma21p) was discovered, with patients presenting with a hepatic phenotype with steatosis and
hypercholesterolemia [97]. Two mutations causing a premature stop codon and one missense mutation
in VMA21 were discovered. Mechanistically, the symptoms of VMA21-CDG patients are the result
of impaired lipophagy due to reduced lysosomal acidification, and patients present with a loss of
sialic acid and galactose on glycoproteins [97]. In yeast, Vma21p interacts with V0 subunit c’ and
thus promotes the assembly of the V0 proteolipid subunits into a ring (Figure 2) [79,80]. In mammals,
VMA21 can also directly interact with subunit a of the V0 domain, and this interaction is dependent
on glycosylation of subunit a (Figure 2) [81,82]. This observation has a two-pronged implication:
efficient glycosylation is reliant on the proper assembly of the V-ATPase, and the proper assembly of
the V-ATPase is reliant on efficient glycosylation. This could function as a quality control mechanism
to abrogate the assembly of a faulty V-ATPase. Most interestingly, in yeast strains lacking Vma21p,
the ER-Golgi SNARE Bos1p (ortholog of mammalian GosR2 [98,99]) was completely absent from COPII
vesicles [100], strengthening the importance of pH homeostasis for functional ER-Golgi trafficking.
Furthermore, missense mutations in the gene coding for putative V-ATPase assembly factors
uncharacterized transmembrane protein 199 (TMEM199, the ortholog of yeast Vma12p) and
coiled-coil-domain containing protein 115 (CCDC115, the ortholog of yeast Vma22p) have also
been found in novel CDGs [101,102]. CCDC115 and TMEM199 are hypothesized to assemble
the membrane-integral V0 domain of the V-ATPase through interactions with subunit a (Figure 2) [83].
In S. cerevisiae, assembly of the V0 domain mediated by Vma21p, Vma12p, and Vma22p occurs at
the ER membrane [103–105], after which the V0 domain is transported to the Golgi and associates
with the V1 domain to form the fully functional V-ATPase complex [40]. In mammals, the exact
mechanism of V-ATPase assembly is still unclear, but as TMEM199 and CCDC115 localize to
the ER, it is suggested that mammalian V-ATPase assembly is analogous to that in yeast [106].
Pathogenic variants in either protein mainly have a hepatic phenotype similar to VMA21-CDG,
although a neurological phenotype is observed for CCDC115-CDG patients. Abnormal glycosylation,
mainly the truncation of glycans through the loss of sialylation and galactosylation, is seen for
both CDGs. This observation corresponds to the mislocalization of especially trans-Golgi-resident
galactosyltransferases, which is consistent with the concomitant acidification of the Golgi apparatus.
In contrast to VMA21-CDG [97], but in line with ATP6V0A2-CDG [48], no disorders in autophagy
were described for TMEM199-CDG and CCDC115-CDG [101,102]. One explanation is that a potential
lysosomal defect was not investigated. Another plausible explanation for this phenomenon is that
TMEM199 and CCDC115 participate in the assembly of a specific V-ATPase for the Golgi apparatus,
while the lysosomal V-ATPase is still assembled regularly in TMEM199-CDG and CCDC115-CDG.
This raises the possibility that TMEM199 and CCDC115 primarily interact with a certain V0a subunit,
likely V0a2 concerning the glycosylation phenotypes in TMEM199-CDG and CCDC115-CDG, to
facilitate the assembly of a Golgi-specific V-ATPase [107–109]. The severity of the symptoms of
ATP6AP1-CDG, ATP6AP2-CDG, and VMA21-CDG patients could stem from a more general role
of these factors in V-ATPase assembly. Incomplete assembly of the V-ATPase might also result in
mislocalization of the V0 domain, as the trafficking of the V0 domain might be pH dependent itself,
thereby amplifying the phenotypes. Aside from their role in CDG, TMEM199 and CCDC115 have
also been implicated in iron metabolism [106] and influenza A virus infection, most probably via
a pH-dependent mechanism [110]. These observations underpin how V-ATPase assembly, glycosylation,
ER-to-Golgi, and intra-Golgi trafficking are intertwined.
Finally, pathogenic variants in the uncharacterized transmembrane protein 165 (TMEM165, also
known as TPARL) leading to CDG have been identified [111], one intronic mutation in the gene coding for
TMEM165 leading to the production of a truncated protein and two missense mutations at sites coding
for highly conserved residues. Patients with TMEM165-CDG mainly present with skeletal and hepatic
abnormalities and an N-glycosylation defect consisting of hyposialylation and hypogalactosylation.
No O-glycosylation abnormalities were observed in these patients. TMEM165 is a putative proton
Int. J. Mol. Sci. 2020, 21, 4654 7 of 28
pump, based on protein sequence homology [111], primarily localizing to the late Golgi apparatus
and potentially maintaining the pH in this compartment (Figure 2). This theory is corroborated by
the similar glycosylation defects observed with TMEM165-CDG and V-ATPase-related CDGs discussed
above. Additionally, depletion of TMEM165 using RNA interference in HEK293 cells revealed a defect
in Golgi galactosylation, which could be rescued by supplementation with manganese [112]. As
manganese is required for the proper functioning of some glycosylation enzymes [113,114], TMEM165
may also be required for manganese homeostasis, perhaps by functioning as a manganese transporter.
2.2. Golgins, GRASPs, GORAB, and Rabs
Vesicle fusion with the Golgi apparatus is initiated by specific capture of vesicles by long coiled-coil
proteins decorating the Golgi membrane: Golgins [57–59,115]. Next to this, Golgins also act as structural
proteins to maintain Golgi architecture [116]. To date, genetic variants in several Golgins have been
identified that affect both retrograde intra-Golgi trafficking and glycosylation. For instance, a nonsense
mutation in the gene coding for GMAP-210 (Figure 3, also known as TRIP11) causes neonatal lethal
skeletal dysplasia in both mice and humans [117]. Similar to GORAB (see below), the phenotypes
in patients carrying loss-of-function mutations in TRIP11 are caused by defective glycosylation of
extracellular matrix proteins. GMAP-210 normally functions as a tether for both ER-to-Golgi and
intra-Golgi vesicles [118,119]. TRIP11 mutant chondrocytes and osteoblasts isolated from mice carrying
this nonsense mutation showed swollen ER and a disrupted Golgi architecture. Patient fibroblasts with
either a heterozygous or homozygous nonsense variant of GMAP-210 showed incomplete glycosylation
of the model secretory protein vesicular stomatitis virus G protein (VSVG) fused to GFP, suggesting
a function of GMAP-210 in trafficking. These mutant cells also showed increased lectin GS-II binding
along cell surfaces, indicating a defect in glycosylation due to GMAP-210 loss-of-function, as lectin
GS-II binds to terminal non-reducing N-acetyl-d-glucosamine, which is normally not present in fully
processed glycoproteins [117]. Hypomorphic mutations, or partial loss-of-function mutations, in
TRIP11 cause a different genetic disorder called odontochondrodysplasia (ODCD) [120], affecting
skeletal and dental development. In contrast to the loss-of-function mutations in TRIP11, secretion is
not affected in ODCD. Glycans on the lysosomal glycoprotein LAMP2 and the extracellular matrix
protein decorin were both abnormal, and synthesis of extracellular matrix proteins was strongly
reduced, leading to disease [120].
Other Golgins also regulate glycosylation, but have not been associated with CDGs. An intronic
splice donor site mutation in the gene coding for Golgin giantin (Figure 3, also known as GOLGB1)
produces a truncated protein, which causes cleft palate in mice, with murine embryos showing an
increase in GS-II lectin binding to terminal GlcNAc moieties within the palatal regions, which is
indicative of incomplete protein glycosylation. In parallel, frontal sections of developing palatal shelves
of giantin loss-of-function mutant mice show increased binding of PNA lectin after desialylation with
neuraminidase, showing an increase in galactosylated O-type mucins on the cell surface [121]. In
addition to giantin, certain membrane tethering proteins, such as giantin, GRASP55, and GRASP65
(Figure 3), are thought to regulate the rate of retrograde trafficking, likely to assure efficient recycling
of glycosylation enzymes to their target Golgi compartment. RNA interference-mediated depletion
of giantin in HeLa cells revealed that this causes aberrant fusion of Golgi cisternae [122]. This, in
turn, caused a two-fold increase in the mobility of the glycosylation enzyme ManII as measured by
fluorescence recovery after photobleaching and accelerated the trafficking of VSVG to the plasma
membrane [123]. Furthermore, siRNA depletion of giantin caused overexpression of sialylated
glycoproteins at the cell surface [123]. Moreover, depletion by RNA interference of GRASP55/65
accelerated the anterograde trafficking of VSVG, independent of ER stress and unconventional protein
secretion, and concurrently decreased the complete glycosylation of VSVG [124].
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the binding affinity of GORAB to Scyl1 or affect the assembly of GORAB in membrane domains,
leading to the dysfunction of GORAB. Loss-of-function mutations in GORAB inhibit the retrieval of
trans-Golgi resident enzyme ST6GAL1 in a COPI-mediated manner, demonstrating the necessity of
GORAB for COPI-mediated intra-Golgi trafficking. Concurrently, GORAB mutant fibroblasts from GO
patients show a reduced abundance of complex terminally sialylated glycans, suggesting deficient
glycosylation by dysfunctional GORAB [125]. Taken together, the observed phenotypes suggest that
GORAB mutations can be considered CDGs.
Once a vesicle has been captured by a Golgin, effectors such as Rab GTPases are recruited (Figure 3).
Rabs exists in a GDP-bound inactive state and are activated by the exchange for GTP through guanine
nucleotide exchange factors (GEFs). This nucleotide exchange results in a conformation switch, which
enables Rabs to recruit specific effectors required for vesicular trafficking. Genetic variants within Rab
proteins are associated with several neurological and metabolic disorders, including Parkinson’s disease
and Neumann–Pick’s disease [135]. Certain Rabs play an active role in retrograde Golgi trafficking,
such as Rab6, which is required for bidirectional transport of cargo at the Golgi [64]. Furthermore,
Rab2 can influence the function of GMAP-210 in COPI vesicle tethering [119], while Rab1, Rab2, Rab4,
and Rab6 can interact with members of the COG complex and thereby tether COPI vesicles to the Golgi
membrane [136]. Rab1, in particular, has also been identified to regulate the Golgi architecture and
function and therefore has an indispensable role in glycosylation [135]. While genetic variants in Rabs
or their regulatory proteins have not been implicated in CDGs thus far, it is conceivable that Rab
dysfunction alters the identity of COPI vesicles, which results in the mislocalization of glycosylation
enzymes. Thus, considering the potential effects of Rab dysfunction on glycosylation, it stands to
reason that Rab CDGs are yet to be identified.
2.3. Conserved Oligomeric Golgi Tethering Complex
After Golgins mediate the capture of Golgi-destined vesicles from the cytosol, the COG complex
functions as a tether to anchor COPI vesicles to the Golgi membrane [137–139]. COG subunits have
been described to interact directly with COPI coat components, as well as with SNAREs and Rab
GTPases involved in Golgi trafficking [68,140–145]. Despite the lack of transmembrane domains in
COG subunits, they are membrane-associated proteins. The COG complex is a hetero-octameric
protein complex, consisting of eight unique subunits COG1-8 (Figure 4). These subunits organize
themselves into two distinct lobes: lobe A consisting of COG1-4 and lobe B consisting of COG5-8. This
in turn also dictates their localization: lobe A is primarily present on the Golgi membrane, while lobe B
localizes to COPI vesicles [145]. The two lobes are bridged by an interaction between COG1 and COG8
through the formation of alpha-helical bundles [68,140]. The COG complex is therefore required for
the trafficking of glycosyltransferases and cargo proteins.
Cellular models of COG-subunit deficiencies show an alteration in glycosylation homeostasis [146].
At a cellular level, the depletion of COG subunits 2, 3, 4, 6, 7, and 8 causes the mislocalization of
glycosylation enzymes MAN2A1, MGAT1, B4GALT1, and ST6GAL1 to COG complex-dependent
vesicles [147,148], demonstrating their necessity in functional glycosylation [149]. Studies in HeLa cells
depleted of COG4 by RNA interference also demonstrated glycosylation defects and the mislocalization
of vesicles containing COG-interacting proteins (GEARs) around the Golgi [138,140,148]. Of note,
the permanent membrane targeting of COG subunits 4, 7, and 8 by fusing them to the transmembrane
protein TMEM115 [150] disrupts the ribbon structure of the Golgi as visualized by electron microscopy,
causing the swelling of cisternae and an increase of spherical, non-cisternal elements [151]. Nevertheless,
membrane-anchoring of COG4 and COG7, but not COG8, rescued the glycosylation defects observed in
their respective CRISPR/Cas9 knockout cell models. The N-terminal attachment of membrane-anchored
COG8 interfered with overall COG structure and function, impeding the rescue of the observed
glycosylation defects [151]. The permanent Golgi anchoring of COG4 and 7 maintains the polarization
of cis- and trans-Golgi markers, but fails to restore a highly organized Golgi structure in COG4 and
7 knockout cells. These data demonstrate that the membrane association of most COG subunits is
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imperative for their function, and likely assists in the correct retrieval of glycosyltransferases to earlier
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Genetic variants causing CDGs have been identified for all COG subunits, except for COG3 [140,
149,152]. Most genetic variants in COG subunits are observed in lobe A subunits COG1 and COG4 and
in lobe B subunit COG8 (Figure 4). While in most CDGs, N-glycosylation is mostly affected, COG-CDGs
show a broader phenotype with defects in both N- and O-glycan biosynthesis [149]. Clinically, patients
of COG-CDGs present with prominent incomplete galactosylation and sialylation [149,153], and this
is true for variants in both lobe A and B subunits. While the variants mostly consist of missense
mutations or truncations for lobe A subunits and full loss-of-function mutations in lobe B subunits,
glycan profiles of patients show the same hypogalactosylation and hyposialylation for both types
of mutations [154,155]. This raises the question of whether mutations in one COG subunit affect
the entire COG complex. Indeed, a variant in one COG subunit is associated with the instability of
another subunit within that lobe, leading to the decrease in protein expression of subunits in the same
lobe [156]. This has been shown for COG1 [153] and COG2 [152] in lobe A and COG6, COG7 [157,158],
and COG8 [159] for lobe B. Moreover, the mutations in COG1 are associated with a decrease in protein
levels of COG8 [153]. Oppositely, a truncation mutant of COG8 also decreases the protein levels of
COG1 [160]. The finding that all eight subunits are required for complete COG function is a possible
explanation for the similarity in glycan profiles of COG-CDGs (see below). However, COG1- and
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COG4-CDG phenotypes are relatively mild, while COG7- and COG8-CDG are much more severe. This
could indicate a differential necessity of COG lobe B over lobe A.
COG-CDGs have mainly been implicated through genetic variants of COG1 and COG4 for lobe A.
Patients with an 80 residue C-terminal truncation of COG1 present with a reduction of galactose and
sialic acid moieties on N- and O-glycans. Consistent with this, fibroblasts isolated from these patients
demonstrate a reduction of sialic acid incorporation on mucin-type O-glycans [153]. A different variant,
an intronic mutation that results in a frameshift and a premature stop codon in exon 7, in COG1 causes
skeletal defects and mental retardation, together with hypogalactosylation and hyposialylation [161].
Moreover, the Brefeldin A assay performed on these patient fibroblasts revealed a retrograde Golgi
trafficking defect. In CHO cells, depletion of COG1 by RNA interference leads to both deficient N- and
O-glycosylation [138,140]. Fibroblasts from a patient with two heterozygous missense and nonsense
mutations, respectively, in COG4 also showed hypogalactosylation and hyposialylation [162,163].
Effects of these variants on other COG subunits were not investigated. Moreover, a patient with
a different missense mutation in COG4 presented with a similar glycosylation defect, but the instability
of the other subunits in COG lobe A was also observed, likely due to the inability to form COG
subcomplexes [164]. Lastly, another amino acid substitution in COG4 was identified causing a rare
form of primordial dwarfism, but patients notably have normal glycosylation of serum proteins [165].
Instead, the extracellular matrix protein decorin is abnormally glycated in these patients, underlying
their pathology.
To date, only a single mutation, an intronic mutation leading to a decrease in COG5 expression, has
been identified in the gene coding for COG lobe B subunit COG5 with mostly neurological symptoms
and similar hypogalactosylation and hyposialylation like in other COG defects [154,166–168]. Several
studies have shown that a single missense mutation in COG6 leads to severe neurological and
hepatological symptoms and can lead to infant mortality [169–172]. The relative severity of COG6-CDG
is likely due to the observed instability of COG lobe B, as COG6-CDG patients also have lower protein
levels of COG5 and COG7. Furthermore, decreased levels of the trans-Golgi SNARE syntaxin-6
were detected, suggesting that stabilization of syntaxin-6 via the COG complex is necessary for its
function [171]. Intronic mutations affecting the mRNA splicing and ultimately causing the decrease of
protein levels of COG7 cause similar glycosylation defects, with patients presenting hyposialylation
in their N- and O-linked glycan biosynthesis [157,158,173]. Another study observed that one specific
variant in COG7, which is associated with infantile mortality [174], causes a loss of sialylation on serum
transferrin and on cell surface proteins of patient fibroblasts [175]. Moreover, this variant in COG7
affects Golgi trafficking as shown by the impaired trafficking of ST3GAL1 from the ER to the trans-Golgi
in patient fibroblasts. A homozygous nonsense mutation in COG8 results in the formation of a truncated
COG8 subunit, lacking 76 C-terminal residues, affecting the interaction between COG8 and COG1.
Patients with this variant present with mild hyposialylation [160]. Similarly, a patient with a different
genetic variant resulting in the truncation of COG8 with the loss of 47 C-terminal residues showed
a similar deficiency in sialylation [159]. COG8-CDG patients present with a severe neurological
phenotype and display a fragmented Golgi apparatus in patient fibroblasts. Overall, the COG defects
demonstrate the importance of efficient tethering of intra-Golgi vesicles and show that even small
changes are enough to destabilize the COG complex, thereby severely affecting glycosylation.
2.4. SNAREs
The final step in the delivery of glycosylation enzymes to the Golgi is SNARE-mediated membrane
fusion. SNARE proteins are classified by the central residue in their SNARE motif: R-SNAREs have
a central arginine residue, while Qa-, Qb-, Qbc-, and Qc-SNAREs have a central glutamine residue.
A tight alpha-helical coiled-coil bundle is formed by one of each type of SNARE motif, provided by
three or four cognate SNARE proteins. These are present on both the vesicular (e.g., COPI vesicle)
and target membranes (e.g., cis-Golgi), and the coiled-coil formation provides enough energy to
fuse the two opposing membranes [176,177]. At the mammalian ER-Golgi interface, four distinct
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SNARE complexes exist: Stx5/GosR2 (also known as GS27 or membrin)/Bet1/Sec22b (also known as
ERS24) for anterograde transport from ER to ERGIC, Stx5/GosR1/Bet1/Ykt6 for anterograde transport
from ERGIC to cis-Golgi, Stx5/GosR1 (also known as GS28)/Bet1L (also known as GS15)/Ykt6 for
retrograde intra-Golgi transport, and Stx18/Sec20/Use1/Sec22b for retrograde transport from cis-Golgi to
ER [98,99,178–191]. While in general, R-SNAREs are present on the vesicular membrane in eukaryotic
cells [177], evidence suggests that the Qc-SNAREs Bet1 and Bet1L function as the vesicular SNAREs at
the ER-Golgi interface [99,188,191–194]. This observation, together with the necessity of Sec1/Munc18
SM) protein Scfd1 in ER-Golgi SNARE fusion, likely implies specificity to the fusogenic SNARE
complex, by inhibiting the formation of non-functional SNARE complexes [30,195–198].
Despite the essential role of SNAREs in Golgi trafficking [99], there is only limited evidence
for a clinical link between glycosylation and genetic variants in SNARE proteins. This also raises
the question of whether SNARE CDGs mostly remain undetected due to a possible severity of
the disease. Contrary to plasma membrane-localized SNARE complexes, ER-Golgi-localized SNARE
complexes lack redundancy, and the loss of a single SNARE protein at this interface might result in
detrimental effects for glycosylation and/or life [98]. Recently, the first CDG related to a SNARE protein
was identified, namely a point mutation in STX5, the gene coding for the Qa-SNARE syntaxin-5 [191].
In animals, the STX5 gene is transcribed to one mRNA, which produces two different isoforms of
Stx5 via an alternative starting codon: 39.6 kDa sized Stx5 Long (Stx5L) and 34.1 kDa sized Stx5
Short (Stx5S) [99,199]. Stx5L is characterized by a 54 residue N-terminal extension with an RKR
(arginine-lysine-arginine) ER-retrieval motif and localizes at ER, ERGIC, and cis-Golgi. In contrast,
Stx5S lacks this RKR ER-retrieval motif and primarily localizes to the Golgi (Figure 4). The point
mutation causes the specific loss of Stx5S through the mutation of the second starting methionine
residue into valine. This loss of the intra-Golgi dominant Qa-SNARE Stx5S results in a severe disorder,
characterized by metabolic and developmental defects and infantile mortality. Microscopy revealed
that this is caused by the mislocalization of glycosylation enzymes to the wrong compartment in
the Golgi apparatus, leading to the reduced incorporation of galactose and sialic acid moieties in
N-glycans and an overrepresentation of immature high-mannose glycans [191].
The Qbc-SNARE SNAP29 has previously also been ascribed a role in Golgi morphology, and
its dysfunction could likely result in glycosylation defects [200]. Of note, several missense and
truncating mutations in SNAP29 have been associated with cerebral dysgenesis, neuropathy, ichthyosis,
and keratoderma syndrome (CEDNIK, a disorder of brain development, facial dysmorphism, and
skin), and Pelizaeus–Merzbacher-like disorder (PMLD, a disorder of brain development and muscle
function) [201–207]. The first report of SNAP29 involvement in CEDNIK noted that no N- and
O-glycosylation defects were observed, although the authors did not describe how the patients were
screened [206]. This result does not exclude that SNAP29 is involved in glycosylation, as, assuming that
custom IEF methods were applied for CDG screening, it is possible that although glycosylation of either
transferrin or apolipoprotein CIII were not affected, other glycosylated proteins were. Additionally,
these methods might not have been sensitive enough to detect an underlying glycosylation disorder, or
only glycosylation in certain tissues could have been affected. Finally, fusion-impaired forms of GosR2
result in a neurological phenotype in patients with progressive myoclonus epilepsy, but have not been
associated with glycosylation defects (Figure 4) [208–210]. It is possible that during these studies,
no diagnostics for glycosylation has been performed or that through a compensatory mechanism,
sufficient glycosylation was maintained. Along these lines, more comprehensive diagnostic screening
procedures might implicate more SNAREs in CDGs.
3. Discussion and Conclusions
The glycosylation process is an essential part of the secretory pathway and is a complex logistic
system. Newly synthesized glycoproteins are shuttled from the ER to the Golgi apparatus, which
acts as a production line that sequentially builds complex branched glycan structures on the proteins.
Moreover, the Golgi can be considered a distribution center that ensures that glycoproteins are modified
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and sorted correctly to their final destinations. As with factories and other logistic systems, having
efficient infrastructure is the key to a high efficiency and fidelity of production and delivery. Each
organelle in the logistic chain needs to function optimally to avoid bottlenecks, and therefore, efficient
coordination amongst organelles is of utmost importance. Here, we discussed how dysfunctional
transport processes affect glycosylation and, in turn, cause a wide array of symptoms including skin
and bone disorders, impaired liver function, and even infantile mortality. Mechanistically, these
pathologies are the result of impaired pH homeostasis in the Golgi, incorrect tethering of Golgi-destined
vesicles, and defective membrane fusion at the Golgi apparatus (Table 1).
In this review, we discussed pathogenic variants in the V-ATPase and associated proteins that
affect Golgi pH homeostasis and glycosylation. Considering that glycosylation enzymes have a broad
pH optimum and that the Golgi has a narrow range in pH (pH 6.7 for cis to pH 6.0 for trans), it
seems unlikely that small defects in pH homeostasis result in a pronounced loss of catalytic activity
of the glycosylation enzymes. Instead, the prevailing theory is that pH affects the trafficking of
glycosylation enzymes to their cognate Golgi compartments and that altering the Golgi pH results
in mislocalization of these enzymes to the wrong compartment [53–55]. This is corroborated by
the observation that Golgi-to-ER recycling mediated by the KDEL receptor is indeed pH-dependent [211]
and by the observation that the ER-Golgi SNARE protein Bos1p is absent from COPII vesicles of
yeast strains lacking the V-ATPase assembly factor Vma21p [100]. Moreover, it has been described
that the luminal pH affects the oligomerization of certain glycosylation enzymes and thereby also
influences their localization [212–219]. Another well-characterized example of pH-mediated protein
sorting is the binding of the mannose-6-phosphate receptor to the mannose-6-phosphate-labeled
cargo destined for the lysosome. Proteins are bound by this receptor in the Golgi and subsequently
released in the more acidic environment of late endosomes [220–222]. Finally, the pH of the TGN is
also important for the correct sorting of the extracellular matrix components laminin and heparan
sulfate proteoglycan to the basolateral surface of polarized epithelial cells [220,223,224]. Taken together,
evidence shows that homeostasis of pH is of crucial importance for trafficking within, from, and to
the Golgi apparatus, and thereby likely a critical factor for glycosylation. This also implicates that
mislocalization of the V-ATPase and associated proteins due to pathogenic mutations in trafficking
proteins such as SNAREs, COG subunits, or Golgins can affect glycosylation.
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Table 1. Overview of membrane trafficking-related CDGs and their phenotypes.
Gene Mutation CDG a ClinicalPhenotype b N-Glycosylation
c Man GlcNAc Gal Sia O-Glycosylation c Screening d References
ATP6V0A2 V66fsX107 X + −−− = = − −− −− IEF, MS [48]
ATP6V0A2 T643fsX683 X + −−− = = − −− n.d. IEF [48]
ATP6V0A2 Q765X X + −−− = = − −− −− IEF, MS [48]
ATP6V0A2 R63X X ++ −−− = = − −− −− IEF, MS [48,225]
ATP6V0A2 K117fsX144 X ++ −−− = = − −− −− IEF, MS [48,225]
ATP6V0A2 n.d. X ++ −−− = = − −− −− IEF, MS [48,225]
ATP6V0A2 D243fsX258 and E442fsX506 X ++ −−− = = − −− = IEF, MS [48]
ATP6V0A2 T280fsX285 X +++ −−− = = − −− −− IEF, MS [48]
ATP6V0A2 E442X X +++ −−− = = − −− = IEF, MS [48]
ATP6AP1 M4281 X + −−− = = −− −− −− IEF, MS [92]
ATP6AP1 L144P X + −−− = = −− −− −− IEF, MS [92]
ATP6AP1 E346K X ++ −−− = = −− −− −− IEF, MS [92]
ATP6AP1 Y313C X ++ −−− = = −− −− −− IEF, MS [92]
ATP6AP2 L98S X ++ −−− = = −− −− = CZE, IEF, MS [93]
ATP6AP2 L98S X + −−− = = −− −− = CZE, IEF, MS [93]
ATP6AP2 R71H X ++ −−− = = −− −− = CZE, IEF, MS [93]
VMA21 n.d.1 X + −− = = −− −− − IEF, MS [97]
VMA21 R18G* X + −− = = −− −− − IEF, MS [97]
VMA21 N63G X + −− = = −− −− − IEF, MS [97]
TMEM199 A7E X + −−− = = − − −−− IEF, MS [102]
TMEM199 A14P X + −−− = = − − = IEF, MS [102]
TMEM199 R31P X + −−− = = − − −−− IEF, MS [102]
CCDC115 L31S X ++ −−− = = −− −− −−− IEF, MS [101]
CCDC115 D11Y X ++ −−− = = −− −− −−− IEF, MS [101]
TMEM165 n.d.2 X ++ −−− = = −− −− = IEF, MS, L [111]
TMEM165 R126C X ++ −−− = = −− −− = IEF, MS, L [111]
TMEM165 R126C and G304R X + −−− = = −− −− IEF, MS, L [111]
GMAP-210 L1668X − +++ −−− = = −− −− = L [117]
GMAP-210 G439VfsX20 and n.d.4 − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 D410Y and E1606LfsX3 − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 Q196X and Q1512X − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 D410Y and I710CfsX19 − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 K541RfsX17 and M1806V − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 Q196X and K998SfsX5 − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
GMAP-210 Q196X and R264X − +++ n.d. n.d. n.d. n.d. n.d. n.d. Blot [120]
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Table 1. Cont.
Gene Mutation CDG a ClinicalPhenotype b N-Glycosylation
c Man GlcNAc Gal Sia O-Glycosylation c Screening d References
GOLGB1 n.d.3 − ++ −−− = = −− −− −−− L [121]
GORAB F8L − ++ −−− = = = −− = MS, L [125]
GORAB K190del − ++ −−− = = = −− = MS, L [125]
GORAB M1? X ++ = = = = = = CZE [127,226]
GORAB E46X X ++ n.d. = = = = n.d. n.d. [127]
GORAB P86RfsX70 X ++ n.d. = = = = n.d. n.d. [127]
GORAB E123X X ++ n.d. = = = = n.d. n.d. [127]
GORAB S175_R221del X ++ n.d. = = = = n.d. n.d. [127]
GORAB Q247X X ++ n.d. = = = = n.d. n.d. [127]
GORAB R262X X ++ n.d. = = = = n.d. n.d. [127]
GORAB F350LfsX26 X ++ n.d. = = = = n.d. n.d. [127]
SCYL1 H392PfsX30 − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [133]
SCYL1 V313CfsX6 and n.d.4 − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [134]
SCYL1 A504PfsX15 and Q546X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [134]
SCYL1 Q57X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 E86X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 A105V − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 V313CfsX6 and Q347X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 n.d.4 − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 D478G − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 A504PfsX15 − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 Q546X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
SCYL1 Q628X − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [132]
COG1 900X X ++ −−− = = −− −− −−− IEF, MS, L [153]
COG1 n.d.4 X ++ −− = = − −− −− IEF, MS [161]
COG2 Y234X and W634G X +++ −− = = − −− n.d. IEF, MS [152]
COG4 L773R X ++ −−− = = = −− −−− IEF, HPLC,MS [162,163]
COG4 E233X X ++ −−− = = = −− −−− IEF, HPLC,MS [162,163]
COG4 R729W X ++ −−− = = = −− = IEF, MS [164]
COG4 G516R X ++ = = = = = = MS [165]
COG5 n.d.4 X +/++ −− + + −− −− −− IEF, MS
[154,166–
168]
COG6 G549V X +++ −− = = − −− −− IEF, HPLC,MS [169–172]
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Table 1. Cont.
Gene Mutation CDG a ClinicalPhenotype b N-Glycosylation
c Man GlcNAc Gal Sia O-Glycosylation c Screening d References
COG7 n.d.4 X +++ −−− = = = −− −−− IEF, L
[157,158,
174,175]
COG7 n.d.4 X +++ −− = = − −− −− IEF, MS [173]
COG8 Y537X X ++ −−− = = − − −−− IEF, MS, L [160]
COG8 F563HfsX4 X ++ −−− = = = − −−− MS, L [159]
STX5 M55V X +++ −−− ++ = = −− −−− IEF, MS, L [191]
SNAP29 R29X − ++ n.d. = = = = n.d. n.d. [201]
SNAP29 L119AfsX15 and n.d.4 − ++ n.d. = = = = n.d. n.d. [202]
SNAP29 R85X − ++ n.d. = = = = n.d. n.d. [203]
SNAP29 T130fsX17 − ++ n.d. = = = = n.d. n.d. [204]
SNAP29 P10fsX42 − ++ n.d. = = = = n.d. n.d. [204]
SNAP29 R90C − ++ n.d. = = = = n.d. n.d. [204]
SNAP29 E89K − ++ n.d. = = = = n.d. n.d. [204,205]
SNAP29 V75fsX28 − +++ = = = = = = ? [206]
SNAP29 S163fsX5 − ++ n.d. = = = = n.d. n.d. [207]
GOSR2 G144W − ++ n.d. n.d. n.d. n.d. n.d. n.d. n.d. [209,210]
GOSR2 K164del − + n.d. n.d. n.d. n.d. n.d. n.d. n.d. [209]
a X, confirmed congenital disorder of glycosylation; -, unconfirmed congenital disorder of glycosylation. b Severity of clinical symptoms. +, mild symptoms; ++, moderate symptoms; +++,
severe symptoms. c Severity of glycosylation phenotype. −−−, strong decrease; −−, moderate decrease; −, mild decrease; =, no change; +, mild increase; ++, moderate increase; +++,
strong increase; n.d., not determined. d CZE, capillary zone electrophoresis; IEF, isoelectric focusing; HPLC, high-performance liquid chromatography; MS, mass spectrometry; L, lectin
staining. 1 New ATG start codon upstream of first exon, causing a frameshift and premature stop codon at c.26-28. 2 Cryptic splice donor site activation. 3 Intronic splice donor site; causes
S793F in ITGB5. 4 Intronic splice site.
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Interestingly, except for Stx5-CDG, all described CDGs in trafficking proteins primarily
demonstrate defects in late glycan modifications such as galactosylation and sialylation (Table 1).
Only in Stx5-CDG, the accumulation of an early-stage high mannose glycan is observed. Why could
defects in early glycosylation steps be underrepresented? We can consider several hypotheses. First,
correct glycosylation is of absolute importance for development [2,5], and despite the redundancy
in glycosylation enzymes, defects affecting early glycosylation reactions might not be conducive to
further development. Therefore, potential pathogenic mutations might remain undetected as they
are non-viable. Second, as disorders of glycosylation are mostly a secondary effect of trafficking
defects, glycosylation disorders might go undiagnosed as they simply have not been screened for
in potential cases such as for GOSR2 mutations [209,210]. Last, early glycosylation defects might
go undiagnosed because common biochemical techniques to measure glycosylation in a clinical
setting, such as isoelectric focusing of transferrin and apolipoprotein CIII [227], mostly interrogate
late glycosylation reactions such as sialylation. Modern advances in clinical diagnostics have added
mass spectrometry of intact transferrin [72] and glycomics on total plasma N-glycans [155]. These two
approaches have enabled measuring all N-glycan structures on circulating serum proteins, thereby
giving a more complete view of the glycosylation defects. This allows clinicians and scientists to identify
more complex glycosylation disorders, including those in trafficking factors. Future advances to
glycosylation screening might include measuring the glycome of all different tissues in the human body
or measuring site-specific glycosylation on a large array of proteins. Understanding trafficking and
glycosylation in different cellular contexts will ultimately further our knowledge of glycobiology and
eventually increase therapeutic options for patients suffering from CDGs. A subcellular understanding
of CDG can pave the road for targeted therapies through, for instance, gene replacement of affected
genes or the development of small molecules to modulate ER-to-Golgi and intra-Golgi transport.
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